These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28475803)

  • 1. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation.
    Pettit NN; Miceli MH; Rivera CG; Narayanan PP; Perissinotti AJ; Hsu M; Delacruz J; Gedrimaite Z; Han Z; Steinbeck J; Pisano J; Seo SK; Paskovaty A
    J Antimicrob Chemother; 2017 Aug; 72(8):2355-2358. PubMed ID: 28475803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.
    Cumpston A; Caddell R; Shillingburg A; Lu X; Wen S; Hamadani M; Craig M; Kanate AS
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4424-8. PubMed ID: 25987632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.
    Durani U; Tosh PK; Barreto JN; Estes LL; Jannetto PJ; Tande AJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4914-8. PubMed ID: 26055378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
    Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
    J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections.
    Pham AN; Bubalo JS; Lewis JS
    Mycoses; 2016 Apr; 59(4):226-233. PubMed ID: 26742659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.
    Krishna G; Ma L; Martinho M; Preston RA; O'Mara E
    J Antimicrob Chemother; 2012 Nov; 67(11):2725-30. PubMed ID: 22833639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posaconazole delayed-release tablets in paediatric haematology-oncology patients.
    Mauro M; Colombini A; Perruccio K; Zama D; D'Amico MR; Calore E; Carraro F; Muggeo P; Tridello G; Baretta V; Cesaro S
    Mycoses; 2020 Jun; 63(6):604-609. PubMed ID: 32246512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posaconazole pharmacokinetics after administration of an intravenous solution, oral suspension, and delayed-release tablet to dogs.
    Kendall J; Papich MG
    Am J Vet Res; 2015 May; 76(5):454-9. PubMed ID: 25909378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.
    Boglione-Kerrien C; Picard S; Tron C; Nimubona S; Gangneux JP; Lalanne S; Lemaitre F; Bellissant E; Verdier MC; Petitcollin A
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):127-134. PubMed ID: 28932906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.
    Leclerc E; Combarel D; Uzunov M; Leblond V; Funck-Brentano C; Zahr N
    Sci Rep; 2018 Jan; 8(1):1681. PubMed ID: 29374234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posaconazole liquid vs tablet formulation in lung transplant recipients.
    Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
    Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents.
    Tragiannidis A; Herbrüggen H; Ahlmann M; Vasileiou E; Gastine S; Thorer H; Fröhlich B; Müller C; Groll AH
    J Antimicrob Chemother; 2019 Dec; 74(12):3573-3578. PubMed ID: 31504563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing liver dysfunction in haematology patients: Switch antifungals, or use the tincture of time?
    Perissinotti AJ; Marini BL
    Mycoses; 2019 Mar; 62(3):214-216. PubMed ID: 30474309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
    Liebenstein TK; Widmer KM; Fallon MJ
    J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of posaconazole plasma concentrations achieved with the delayed-release tablets in Korean high-risk patients with haematologic malignancy.
    Chae H; Cho SY; Yi Y; Lee JJ; Cha K; Kim M; Kim Y; Kim YJ; Kim HJ; Lee DG
    Mycoses; 2020 Feb; 63(2):131-138. PubMed ID: 31698506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.
    Kersemaekers WM; Dogterom P; Xu J; Marcantonio EE; de Greef R; Waskin H; van Iersel ML
    Antimicrob Agents Chemother; 2015; 59(6):3385-9. PubMed ID: 25824210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of serum concentrations between different dosing strategies of posaconazole delayed-release tablet at a large academic medical centre.
    Welch S; Pallotta A; Weber C; Siebenaller C; Cober E; Neuner E
    Mycoses; 2017 Apr; 60(4):241-243. PubMed ID: 27910211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients.
    DiPippo AJ; Rausch CR; Kontoyiannis DP
    Mycoses; 2019 Jan; 62(1):81-86. PubMed ID: 30230043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.
    Jung DS; Tverdek FP; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6993-5. PubMed ID: 25199774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed-release tablet and intravenous posaconazole.
    Bernardo V; Miles A; Fernandez AJ; Liverman R; Tippett A; Yildirim I
    Pediatr Transplant; 2020 Sep; 24(6):e13777. PubMed ID: 32639095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.